Close
More Choices in PSA Tests: Laboratorians
Only Siemens can equip your cancer center, hospital or reference laboratory with the full menu of PSA tests demanded by today’s healthcare professionals, including Complexed PSA and Third Generation PSA assays that are alternatives to traditional PSA tests. The Siemens portfolio of PSA assays provides your healthcare clients with more choices to aid in prostate cancer detection, monitoring and follow-up.
The Siemens Portfolio of PSA Assays
PSA tests run on ADVIA Centaur®, IMMULITE® and Dimension® systems ensure cost-effectiveness and fast turnaround times.
| ADVIA Centaur CP | ADVIA Centaur XP | IMMULITE 1000 | IMMULITE 2000 | IMMULITE 2500 | Dimension® ExL | Dimension Vista® | Dimension® RxL Max® | Dimesion Xpand® Plus |
|---|---|---|---|---|---|---|---|---|
| PSA | PSA | PSA | PSA | PSA | PSA1 | PSA2 | PSA | PSA |
| fPSA1 | fPSA1 | fPSA | fPSA | fPSA2 | fPSA1 | fPSA2 | fPSA | fPSA |
| Complexed PSA | Complexed PSA | Third Generation PSA | Third Generation PSA | Third Generation PSA | - | - | - | - |
1. In development
2. Not Available in the U.S.
PSA Test
The PSA assay from Siemens, measuring total serum PSA, is the classical screening method to aid in the detection of prostate cancer.
- Quantitatively measures prostate specific antigen in serum
- Clinically accepted by the NCCN, NACB and EGTM for both detection and monitoring
- Used in conjunction with a digital rectum examination (DRE)
Third Generation PSA Test
Our Third Generation PSA assay aids in the detection of prostate cancer and is used as an adjunctive test to aid in the management of prostate cancer patients.
- Improved confidence in patient management
- Increased therapeutic intervention options through earlier detection of recurrence in conjunction with the clinical evaluation of the patient1
- Approved for prostate cancer screening in conjunction with a digital rectum examination (DRE)
Free PSA Test
Our fPSA assay helps to guide decision-making for patients in the diagnostic gray zone (4.0–10 ng/mL total serum PSA).
- Percent free PSA assessment may help to reduce unnecessary biopsies2,3
- It helps to differentiate cancer from benign prostatic hyperplasia
- Percent free PSA is lower in prostate cancer than in benign prostate hyperplasia2,3
Complexed PSA Test
The Siemens proprietary Complexed PSA is an alternative to traditional PSA testing for frontline screening.
- PSA complexed with alpha-1-antichymotrypsin (ACT) comprises a higher proportion of PSA in men with prostate cancer4-6
- It is recommended by the NCCN as a frontline screening test
- It is used in conjunction with a digital rectum examination (DRE)
Assay Ranges and Performance Characteristics
| System | Assay | Reportable Range |
|---|---|---|
| ADVIA Centaur® CP/XP | PSA | 0.01 ng/mL - 100 ng/mL |
| Complexed PSA | 0.03 ng/mL - 100 ng/mL | |
| IMMULITE 1000/2000/2500 | PSA | 0.04 ng/mL - 150 ng/mL |
| fPSA | 0.07 ng/mL - 25 ng/mL | |
| Third Generation PSA | 0.003 ng/mL - 20 ng/mL | |
| Dimension® RxL Max®/Xpand Plus® | PSA | 0.05 ng/mL - 100 ng/mL |
| fPSA | 0.05 ng/mL - 45 ng/mL | |
| Dimension Vista® | PSA | 0.010 ng/mL - 100 ng/mL |
| fPSA | 0.015 ng/mL - 20 ng/mL |
Links
American Cancer Society
American Urological Association
American Urological Association Foundation
European Group on Tumor Markers
European Association of Urology
National Academy of Clinical Biochemistry
National Comprehensive Cancer Network
National Institute of Cancer
Prostate Cancer Foundation
1: Shen, et al. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy. J of Urol 2005; 173; 777-780.
2: Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, deKernion JB, Walsh PC, Scardino PT, Lange PH, Subong EN, Parson RE, Gasior GH, Loveland KG, Southwick PC. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998 May 20;279(19):1542-7.
3: Lilja, et al. Significance of different molecular forms of serum PSA. Urol C Clin North Am 1993; 20:681:686.
4: Brawer MK, Cheli CD, Neaman IE, Goldblatt J, Smith C, Schwartz MK, Bruzek DJ,Morris DL, Sokoll LJ, Chan DW, Yeung KK, Partin AW, Allard WJ. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J Urol. 2000 Nov;164(5):1671-2.
5: Lilja H, Christtensson A, Matikainen M-T, et al. Prostate-specific antigen occurs predominantly in complex alpha-1-antichymotrypsin. Clin Chem 1991 ; 7 :1618-25.
6: Stenman UH, Leinonen J, Alfthan H, et al. A complex between prostate-specific antigen and alpha-1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991; 51: 222-6.
